TScan Therapeutics board members Nicholson and Gruia resign effective October 13, 2026
The company filled resulting committee vacancies with existing directors Stephen Biggar and R. Keith Woods.
TScan Therapeutics, Inc. disclosed in an 8-K filing that Garry Nicholson and Gabriela Gruia, M.D., resigned from the company's Board of Directors and each committee on which they served, effective October 13, 2026.1
The company stated that the departures were not tied to any disagreement with the company over its operations, practices, or policies.1
Following the resignations, Stephen Biggar and R. Keith Woods were named to the Nominating and Corporate Governance Committee, as member and chairperson respectively, effective October 13, 2026.1 As a result, that committee now consists of R. Keith Woods, Katina Dorton and Stephen Biggar.1
The filing also noted that the Audit Committee now consists of Katina Dorton, Barbara Klencke and R. Keith Woods.1
The 8-K was signed on October 16, 2026 by Gavin MacBeath, Ph.D., the company's Chief Executive Officer, as filed with the Securities and Exchange Commission. TScan Therapeutics trades on The Nasdaq Global Market under the ticker TCRX, with principal executive offices in Waltham, Massachusetts.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.